{"id":3732,"date":"2015-10-25T09:44:32","date_gmt":"2015-10-25T09:44:32","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=3732"},"modified":"2017-01-06T12:23:28","modified_gmt":"2017-01-06T12:23:28","slug":"insight-of-various-medical-management-of-oral-leukoplakia","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol8octoberspledition\/insight-of-various-medical-management-of-oral-leukoplakia\/","title":{"rendered":"Insight of Various Medical Management of Oral Leukoplakia"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

OL is a predominantly white lesion of the oral mucosa that cannot be characterized as any other definable lesion1<\/sup> Such a definition, also adopted by the World Health Organization, is the result of the effort of an international group of experts who met in Uppsala in 1994 to review leukoplakia definitions and classifications on the basis of previously published work2,3 <\/sup><\/p>\n

OL prevalence in the general population varies from less than 1 to more than 5 percent.3-7<\/sup>.<\/p>\n

Clinical variants<\/strong><\/p>\n

There are two clinical variants: 1) Homogeneous leukoplakia, a lesion of uniform flat appearance that may exhibit superficial irregularities, but with consistent texture throughout; and 2) non-homogeneous leukoplakia, a predominantly white or white and red lesion (erythroleukoplakia) with an irregular texture that may present as a flat, nodular, or exophytic lesion.<\/p>\n

Management of leukoplakia\u2014Leukoplakia is a lesion which is mostly asymptomatic it has got a tendency to change into squamous cell carcinoma. The rate of malignant transformation varies from almost 0 percent to about 20 percent in age group one to thirty years.8-10<\/sup> Toludine blue plays a vital role in detection of early dysplastic changes in precancerous lesions. It is the useful chairside diagnostic test which can be performed within 5 min time with high sensitivity of 100% and specificity of 92%.11<\/sup><\/p>\n

A medline search from 1983 to 2014 was conducted.\u00a0 The aim was to assess the evidence of efficacy for treatments for leukoplakia.<\/p>\n

Various treatment modalities for the treatment of leukoplakia.<\/strong><\/p>\n

Carotenoids<\/strong><\/p>\n

Beta-carotene<\/strong><\/p>\n

The use of beta-carotene has been recommended in order to prevent OL and possibly oral cancer.12-14<\/sup> The potential benefits and protective effects against cancer are possibly related to its antioxidizing action.15-17<\/sup> This function is accomplished through a ligation between beta-carotene and oxygen, which is an unstable reactive molecule, thus diminishing the damaging effects of free radicals.17<\/sup>According to Liede et al.15<\/sup>, a diet supplemented with beta-carotene can prevent changes in the oral mucosa, especially in smoker patients, who present low serum levels of vitamin C and beta-carotene when compared to non-smokers. It has also been shown that beta-carotene has a better therapeutic clinic response in the prevention of OL lesions, and in smoker patients than in the non-smoker ones.18<\/sup><\/p>\n

Lycopene<\/strong><\/p>\n

Lycopene is a carotenoid without provitamin A action. Lycopene is considered one of most efficient biological antioxidizing agent.19<\/sup> There is a positive relationship between lycopene consumption and a reduction in the risk of the development of degenerative diseases caused by free radicals, such as cancer and cardiovascular diseases20<\/sup> Lycopene is believed to modify intercellular exchange junctions, and so effective in potentially malignant disorders. 19<\/sup><\/p>\n

Lycopene (from the New Latin word Lycopersicum <\/em>for the name of tomato species) is a bright red carotene and carotenoid pigment. It is a phytochemical found in tomatoes and other red fruits and vegetables, such as red carrots, red bell peppers, watermelons, and papayas (but not strawberries or cherries). Although lycopene is chemically a carotene, it has no vitamin A activity. Orly Livny, et al. <\/em>studied the role of lycopene and \u03b2\u2011carotene and found that lycopene strongly and dose dependently inhibited proliferation of KB\u20111 human oral tumor cells. \u03b2\u2011Carotene was a far less\u2011effective growth inhibitor.21<\/sup> The results of their study further supported the hypothesis that carotenoids, in general, and lycopene, in particular, may be effective anticarcinogenic agents in oral carcinogenesis.<\/p>\n

Further, numerous other potentially beneficial compounds are present in tomatoes and their complex interactions among multiple components may contribute to the anticancer properties of tomatoes.[22,23]\n

Vitamins<\/strong><\/p>\n

Vitamin A<\/strong><\/p>\n

The current definition of retinoid includes all the natural and synthetic compounds with an activity similar to that of Vitamin A. \u00a0Retinoic acid is obtained from carotene and animal products such as meat, milk, and eggs, which, while in the intestine, are converted, respectively, into retinal and retinol [24-27]. Supplementation with retinoids for OL treatment began in the 1960s. However, this treatment was not widely accepted due to its side effects\u2014hypervitaminosis, toxicity, teratogenic effects, and alterations in various organic systems [28].<\/p>\n

13-cRA is the retinoid recommended for OL treatment. The use of 13-cRA has been shown to be effective in resolving OL [25,26]. However, the high recurrence rates after short periods of discontinuance, together with its side effects, are limiting factors [25, 26,28].<\/p>\n

A study conducted by Olson et al reported that complete remission of OL was observed in 57% of patients who received vitamin A about 2,00,000 IU. 29<\/sup> In an other study patients with OL treated by beta-carotene (180 mg\/week) plus vitamin A (100.000 IU\/week) showed significant results. During the trial period, all patients continued to chew tobacco-containing betel quids [30].<\/p>\n

The systemic use of retinoids may lead to severe adverse effects, especially in individuals who need high doses of medication or long-term treat\u00adment. The toxicity seems to be dose-dependent and recurrences are common after the discontinuation of its use (31,32,35).<\/sup> Therefore, a close follow-up of these patients is mandatory. On the other hand, the topical administration of retinoids allows the application of higher concentrations of the drug directly on the lesion but with less adverse effects 31,33<\/sup>.<\/p>\n

One study reported that all 26 patients using topical 0.05% tretinoin gel four times a day for 3.5 years showed signs of clinical improvement. However, 27% showed total remission and 40% of these patients had recurrence of the disease after the discontinuation of the treatment35<\/sup><\/p>\n

In one study, patients received a fixed dose of 13-cRA (10 mg\/day) plus an escalating dose (beginning at 800 IU\/day, until 2000 IU\/day) for 4 months. Seventy-one percent of OL patients had complete clinical responses.36<\/sup><\/p>\n

Fenretinide<\/strong><\/p>\n

Fenretinide (4-HPR) or N-(4-hydroxyphenyl) retinamide is a vitamin A analogue that was synthesized in the United States during the late 1960s. This retinoid shows a preferential accumulation in breast instead of liver [37], is effective in the inhibition of chemically induced mammary carcinoma in rats [38], and has proven to be less toxic than many other vitamin A analogues [38,39]. A characteristic feature of 4-HPR is its ability to inhibit cell growth through the induction of apoptosis with mechanisms that may be both receptor-dependent and receptor-independent. Chemopreventive efficacy of fenretinide has been investigated in clinical trials targeted at different organs [40-42]. A phase II trial of 4-HPR (200 mg\/day) was carried out for 3 months in OL patients who had not responded (\u201cde novo\u201d resistance) or who had responded and then relapsed (acquired resistance) to the previous treatment with natural retinoids. Of 35 patients with retinoid-resistant OL, no patient had complete responses and 12 (34.3%) had partial responses to 4-HPR. Nine patients had clinical responses within 9 months of stopping 4-HPR. Toxicity was minimal and compliance was excellent [43]. Systemic use of 4-HPR with 200 mg\/day for 3 months in 35 patients demonstrated partial clinical resolution of OL of 12 patients.<\/p>\n

\u03b1-Tocoferol (Vitamin E)<\/strong><\/p>\n

\u00a0\u03b1<\/em>-Tocoferol (AT) is the commonest and most active form of vitamin E. It is found in plant oil, margarine, and green leaves [44\u201347]. The recommended daily limit rates are 10 mg\/day for adult men and 8 mg\/day for adult women [48]. Its absorption rate is reduced when consumption exceeds 30mg\/day [49]. \u03b1<\/em>– Tocoferol is an effective antioxidant at high levels of oxygen, protecting cellular membranes from lipidic peroxidation [45,46, 50,51]. Supplementation with AT led to a significant rise in the concentration of this antioxidant in the plasma.<\/p>\n

Benner et al. [52] evaluated the toxicity and efficacy of AT in 43 patients with OL in use of 400 IU twice daily for 24 weeks. Follow-up was performed at 6, 12, and 24 weeks after the beginning of treatment to assess toxicity, clinical response, and serum AT levels. It was observed that 10 patients (23%) had complete clinical remission of lesion and 10 (23%) had a partial clinical response. Nine (21%) had histologic responses (complete reversal of dysplasia to normal epithelium). Mean serum AT levels were 16.1 \u03bc<\/em>g\/mL at baseline and increased to 34.29 \u03bc<\/em>g\/mL after 24 weeks of treatment.<\/p>\n

L-Ascorbic Acid (Vitamin C)<\/strong><\/p>\n

L-ascorbic acid (L-AA), the so-called vitamin C, is found in citrous fruits such as kiwi, strawberries, papaya, and mango. Recommended daily allowance for ascorbic acid ranges between 100\u2013120 mg\/per day for adults [53]. It has been suggested that a daily intake of at least 140 mg\/day is required for smokers because they usually present a reduction of the L-AA concentration in serum leukocytes [54].<\/p>\n

L-AA has antioxidizing properties and reacts with superoxide produced as a result of the cells normal metabolic processes; this inactivation of superoxide inhibits the formation of nitrosamines during protein digestion and helps avoid damage to DNA and cellular proteins [55]. L-AA toxicity does not occur, since vitamin is water-soluble and a decrease in absorption efficiency occurs when consumption exceeds 180 mg\/day [56]. There are no studies regarding the efficacy of the use of L-AA alone for OL treatment.<\/p>\n

Bleomycin<\/strong><\/p>\n

Bleomycin with iontophoresis has been studied in the treatment of leukoplakia and papillomas of the head and neck region.57<\/sup> This method of application was not effective for malignant lesions, but was effective at removing leukoplakia of the oral mucosa. A single case of the complete resolution of hyperkeratotic leukoplakia with atypia using local injections of 5 <\/em>mg of bleomycin weekly in eight treatments has been reported.58<\/sup> Six patients with OL were treated with a daily topical application of bleomycin in dimethylsulphoxide (DMSO) with 12 to 15 application.59<\/sup> Repeat biopsies from 10 to 84 days after therapy demonstrated reduction in keratinization and dysplasia. The authors assumed total absorption of all topically applied bleomycin, yielding a maximum 15-mg systemic dose. This is well below the doses used in the usual systemic therapy.<\/p>\n

Green tea<\/strong><\/p>\n

Green tea and its major polyphenols constituents, tea catechins, have been shown to have many health benefits including cancer prevention. Tea catechins and tea catechin etabolites\/catabolites are bioavailable in the systemic circulation after oral intake of green tea or green tea catechins. Tea pigments are the oxidized product of 40% green tea polyphenols and are composed primarily of theaflavins and thearubigins. Applying the tea extracts directly to the lesions may help improve the local concentrations of the active constituents.<\/p>\n

A limited number of chemoprevention trials of green tea or green tea catechins have been conducted to date and have observed potential preventive activity for oral, prostate, and colorectal cancer. Emerging data from multiple ongoing intervention trials will further contribute to defining the cancer preventive activity of green tea or green tea catechins60<\/sup>.<\/p>\n

Spirulina<\/strong><\/p>\n

The blue\u2011green microalgae Spirulina<\/em>, used in daily diets by natives of Africa and America, have been found to be a rich natural source of proteins, carotenoids, and other micronutrients. Experimental studies in animal models have demonstrated an inhibitory effect of Spirulina <\/em>algae on oral carcinogenesis.<\/p>\n

Mathew, et al. (1995) evaluated the chemopreventive activity of Spirulina fusiformis (1 g\/day for 12 months) in reversing OL in pan tobacco chewers in Kerala, India. They observed complete regression of lesions in 20 of 44 (45%) subjects supplemented with S. fusiformis, as opposed to 3 of 43 (7%) in the subjects on placebo (P < 0.0001). When stratified by the type of leukoplakia, the response was more pronounced in homogeneous lesions: Complete regression was seen in 16 of 28 (57%) subjects with homogeneous leukoplakia, 2 of 8 with erythroplakia, 2 of 4 with verrucous leukoplakia, and 0 of 4 with\u00a0ulcerated and nodular lesions.[61]\n

Celecoxib<\/strong><\/p>\n

The epithelial growth factor receptor (EGFR) is expressed in a wide variety of malignant tumors including head and neck, colon, pancreatic, non-small cell lung, breast, kidney, ovarian, bladder carcinomas and gliomas (62-64). The incidence of EGFR expression in head and neck squamous cell carcinoma (HNSCC) is over 90%, suggesting that EGFR inhibition may be effective in HNSCC (65-67).<\/p>\n

A broad range of laboratory investigations, animal models, and epidemiological studies provide evidence that inhibition of cyclooxygenase-2 (COX-2) pathways may contribute to cancer treatment in general (68-70) and HNSCC in particular (71,72). In HNSCC, COX-2 is expressed in both tumor tissue and adjacent epithelium, with increased expression in invasive carcinoma compared to normal epithelium. COX-2 inhibition has been shown to result in cell growth inhibition in HNSCC cell lines (73).<\/p>\n

COX-2 levels increased progressively throughout all stages of carcinogenesis. This may reflect a role for COX-2 in this process, further supporting the rationale for COX-2 inhibition as a valid strategy for cancer chemoprevention.<\/p>\n

Acitretin <\/strong><\/p>\n

Acitretin is a synthetic aromatic retinoid that is considered as a option in the treatment of severe keratinisation disorders. Acitretin is a free acid of etretinate and its main metabolite, therapeutic activity and side effects, including teratogenecity, are identical to those of etretinate. These side effects make a topical form of actitretin with no reduced systemic adverse effects desirable.<\/p>\n

In a study conducted by GM Gaeta et a74<\/sup> , they concluded that 71% of patient showed clinical remission or marked improvement. The mucoadhesive tablet of topical acitretin are efficacious in the treatment of OL without systemic side effects.<\/p>\n

\u00a0<\/strong>Photodynamic Therapy<\/strong><\/p>\n

\u00a0<\/strong>Photodynamic therapy (PDT) is a noninvasive method for the treatment of premalignant lesions and head and neck cancers [75]. The principle of PDT is a nonthermal photochemical reaction, which requires the simultaneous presence of a photosensitising drug (photosensitiser), oxygen, and visible light. After a period to allow the photosensitiser to collect in the target tissue, the photosensitiser is activated by exposure to low-power visible light of a drug-specific wavelength. Mainly, the light source consists of a portable diode laser and the light is transmitted via laser fibres to or into the tumour. Illumination of the tumour by light at the activating wavelength results in the destruction of cells by a nonfree radical oxidative process. These reactive oxygen species may damage crucial cell components, such as structural proteins, enzymes, DNA, and phospholipids. PDT is a cold photochemical reaction, and the photosensitizing agents are of inherently low systemic toxicity. PDT damage heals mainly by regeneration rather than scarring. Due to the organ preserving principle of PDT, important structures are maintained with good functional and cosmetic outcome [76,77].<\/p>\n

Four photosensitisers have been approved so far: (1) photofrin has been approved in many countries for the treatment of oesophagus cancer and lung cancer; (2) 5-Aminolaevulinic acid (ALA) was also approved in several countries for the treatment of skin cancer; (3) verteporfin for the treatment of macular degeneration (4) foscan is the only photosensitiser that has been approved for the treatment of advanced squamous cell carcinoma of the head and neck in Europe in the year 2001. Only for very superficial skin lesions or\u00a0premalignant lesions of the oral mucosa, the ALA can be applied topically. For all other indications intravenous application is mandatory [78].<\/p>\n

Chen et al. [79] treated 24 patients with OL using 20% ALA-PDT, once a week; another 24 patients used 20% ALA-PDT twice a week. In the latter group, 8 completely responded to the treatment, 16 partially responded, and 9 did not. All patients from the twice-a-week group responded significantly better than those treated only once a week.<\/p>\n

Conclusion<\/strong><\/p>\n

Dentist and general practitioner pay an essential role in the early diagnosis of leukoplakia which is usually asymptomatic and removal of possible factors involved in its etiology such as smoking is necessary in reducing the rate of malignant transformation. Though many trials have been done to find new treatment modalities for leukoplakia there has been no satisfactory treatment for leukoplakia so far. It can be concluded that, although some treatments may be effective in healing OL, they do not seem to be able to prevent relapses and malignant change. For this reason, OLs need to be regularly followed up by the clinician, regardless of their response to topical or systemic treatment, including clinical resolution and instructed to avoid the major risk factors of oral epithelial dysplasia, especially tobacco usage and alcohol consumption.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994.\u00a0International Collaborative Group on Oral White Lesions. J Oral Pathol Med 1996;25:49-54.<\/li>\n
  2. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46:518-39.<\/li>\n
  3. Axell T, Holmstrup P, Kramer I, Pindborg JJ, Shear M. International seminar on oral leucoplakia and associated lesions related to tobacco habits. Community Dent Oral Epidemiol 1984;12:145-54.<\/li>\n
  4. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol 1986;61:373-81.<\/li>\n
  5. Axell T. Occurrence of leukoplakia and some other oral white lesions among 20,333 adult Swedish people. Community Dent Oral Epidemiol 1987;15:46-51.<\/li>\n
  6. Ikeda N, Ishii T, Iida S, Kawai T. Epidemiological study of oral leukoplakia based on mass screening for oral mucosal diseases in a selected Japanese population. Community Dent Oral Epidemiol 1991;19:160-3<\/li>\n
  7. Reichart PA. Oral mucosal lesions in a representative cross-sectional study of aging Germans. Community Dent Oral Epidemiol 2000;28:390-8.<\/li>\n
  8. Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984;53:563-8.<\/li>\n
  9. Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res 1987;95:449-55.<\/li>\n
  10. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a followup study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34:270-5.<\/li>\n
  11. Toludine Blue-A Review with a case report, Manigandan T, Kishorekumar S, Nithya J, Kavitaa N, Kirthuika K. Research Journal of Pharmaceutical, Biological and chemical sciences, Mar-Apr 2014, 5 (2) 1894-99<\/li>\n
  12. \u00a0G. Britton, \u2015Structure and properties of carotenoids in relation to function,\u2016 The FASEB Journal, vol. 9, no. 15, pp. 1551\u20131558, 1995.<\/li>\n
  13. R. S. Parker, \u2015Absorption, metabolism, and transport of carotenoids,\u2016 The FASEB Journal, vol. 10, no. 5, pp. 542\u2013551, 1996. View at Scopus<\/li>\n
  14. R. Sankaranarayanan, B. Mathew, C. Varghese, et al., \u2015Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment,\u2016 Oral Oncology, vol. 33, no. 4, pp. 231\u2013236, 1997. View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus<\/li>\n
  15. K. Liede, J. Hietanen, L. Saxen, et al., \u2015Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers,\u2016 Oral Diseases, vol. 4, no. 2, pp. 78\u201383, 1998. View at Scopus<\/li>\n
  16. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas, et al., \u2015A clinical trial of antioxidant supplements in the treatment of oral leukoplakia,\u2016 Oral Surgery, Oral Medicine, Oral Pathology, vol. 78, no. 4, pp. 462\u2013468, 1994. View at Scopus<\/li>\n
  17. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas, J. S. Thompson, R. B. Brandt, and V. N. Singh, \u2015Use of antioxidant supplements in the treatment of human oral leukoplakia: review of the literature and current studies,\u2016 Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 81, no. 1, pp. 5\u201314, 1996. View at Scopus<\/li>\n
  18. \u00a0K. Malaker, B. J. Anderson, W. A. Beecroft, and D. I. Hodson, \u2015Management of oral mucosal dysplasia with \u03b2-carotene retinoic acid: a pilot cross-over study,\u2016 Cancer Detection and Prevention, vol. 15, no. 5, pp. 335\u2013340, 1991.<\/li>\n
  19. A. V. Rao and S. Agarwal, \u2015Role of antioxidant lycopene in cancer and heart disease,\u2016 Journal of the American College of Nutrition, vol. 19, no. 5, pp. 563\u2013569, 2000. View at Scopus<\/li>\n
  20. G. Riccioni, B. Mancini, E. Di Ilio, T. Bucciarelli, and N. D’Orazio, \u2015Protective effect of lycopene in cardiovascular disease,\u2016 European Review for Medical and Pharmacological Sciences, vol. 12, no. 3, pp. 183\u2013190, 2008.<\/li>\n
  21. Livny O, Kaplan I, Reifen R, Polak\u2011Charcon S, Madar Z,Schwartz B. Lycopene Inhibits Proliferation and Enhances Gap\u2011Junction Communication of KB\u20111 Human Oral Tumor Cells. J Nutr 2002;132:123754\u20119.<\/li>\n
  22. Giovannucci E. Tomatoes, Tomato\u2011Based Products, Lycopene, and Cancer: Review of the Epidemiologic Literature. J Natl Cancer Inst 1999;9:317\u201131.<\/li>\n
  23. Giovannucci E. A Review of Epidemiologic Studies of Tomatoes,Lycopene, and Prostate Cancer. Exp Biol Med 2002;227:10852\u20119.<\/li>\n
  24. S. T. Mayne, \u201cBeta-carotene, carotenoids, and disease prevention in humans,\u201d The FASEB Journal<\/em>, vol. 10, no. 7, pp. 690\u2013 701, 1996.<\/li>\n
  25. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas, et al., \u201cA clinical trial of antioxidant supplements in the treatment of oral leukoplakia,\u201d Oral Surgery, Oral Medicine, Oral Pathology<\/em>,\u00a0vol. 78, no. 4, pp. 462\u2013468, 1994.<\/li>\n
  26. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas, J. S. Thompson, R. B. Brandt, and V. N. Singh, \u201cUse of antioxidant supplements in the treatment of human oral leukoplakia: review of the literature and current studies,\u201d Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics<\/em>, vol. 81, no. 1, pp. 5\u201314, 1996.<\/li>\n
  27. R. D. Azulay and D. R. Azulay, \u201cAtualizac\u00b8\u02dcao em Retin \u00b4 oides,\u201d in Dermatologia<\/em>, p. 516, Guanabara-Koogan Publishing, Rio de Janeiro, Brazil, 2nd edition, 1999.<\/li>\n
  28. J. A. Olson, \u201cCarotenoids and human health,\u201d Archivos Latinoamericanos de Nutricion<\/em>, vol. 49, no. 3, supplement 1, pp. 7S\u201311S, 1999.<\/li>\n
  29. H. F. Stich, A. P. Hornby, B. Mathew, R. Sankaranarayanan, and M. Krishnan Nair, \u201cResponse of oral leukoplakias to the administration of vitamin A,\u201d Cancer Letters<\/em>, vol. 40, no. 1, pp. 93\u2013101, 1988.<\/li>\n
  30. H. F. Stich, M. P. Rosin, A. P. Hornby, B. Mathew, R. Sankaranarayanan, and M. Krishnan Nair, \u201cRemission of oral leukoplakias and micronuclei in tobacco\/betel quid chewers treated with \u03b2<\/em>-carotene and with \u03b2<\/em>-carotene plus vitamin A,\u201d International Journal of Cancer<\/em>, vol. 42, no. 2, pp. 195\u2013199, 1988.<\/li>\n
  31. Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions – focus on topical therapy. Cancer. 2002;95(6):1258-64.<\/li>\n
  32. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ. 2002;66(8):896-902.<\/li>\n
  33. Pimenta FJ, Cordeiro GT, Pimenta LG, Viana MB, Lopes J, Gomez MV, et al. Molecular alterations in the tumor suppressor gene WWOX in oral leuko\u00adplakias. Oral Oncol. 2008;44(8):753-58.<\/li>\n
  34. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer larynx pre\u00adservation and cancer chemoprevention: the seventeenth annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Research. 1993;53(21):5113-20.<\/li>\n
  35. Epstein JB, Gorsky M. Topical application of vitamin a to oral leukoplakia- a clinical case series. Cancer. 1999;86(6):921-7.<\/li>\n
  36. I. W. Dimery, W. K. Hong, J. J. Lee, et al., \u2015Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity,\u2016 Annals of Oncology, vol. 8, no. 1, pp. 85\u201389, 1997.<\/li>\n
  37. M. B. Sporn and D. L. Newton, \u201cChemoprevention of cancer with retinoids,\u201d Federation Proceedings<\/em>, vol. 38, no. 11, pp.2528\u20132534, 1979.<\/li>\n
  38. R. C. Moon, H. J. Thompson, P. J. Becci, et al., \u201cN-(4-hydroxyphenyl)retinamide, a new retinoid for prevention ofbreast cancer in the rat,\u201d Cancer Research<\/em>, vol. 39, no. 4, pp. 1339\u20131346, 1979.<\/li>\n
  39. J. D. Paulson, J. W. Oldham, R. F. Preston, and D. Newman, \u201cLack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide,\u201d Fundamental and Applied\u00a0<\/em>Toxicology<\/em>, vol. 5, no. 1, pp. 144\u2013150, 1985.<\/li>\n
  40. F. Chiesa, N. Tradati, R. Grigolato, et al., \u201cRandomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results,\u201d International Journal of Cancer<\/em>, vol. 115, no. 4, pp. 625\u2013629, 2005.<\/li>\n
  41. R. Torrisi and A. Decensi, \u201cFenretinide and cancer prevention,\u201d Current Oncology Reports<\/em>, vol. 2, no. 3, pp. 263\u2013270, 2000.<\/li>\n
  42. F. Chiesa, N. Tradati,M.Marazza, et al., \u201cFenretinide (4-HPR) in chemoprevention of oral leukoplakia,\u201d Journal of Cellular Biochemistry<\/em>, vol. 52, supplement 17, pp. 255\u2013261, 1993.<\/li>\n
  43. S. M. Lippman, J. J. Lee, J. W. Martin, et al., \u201cFenretinide activity in retinoid-resistant oral leukoplakia,\u201d Clinical Cancer Research<\/em>, vol. 12, no. 10, pp. 3109\u20133114, 2006.<\/li>\n
  44. G. W. Burton and M. G. Traber, \u201cVitamin E: antioxidant activity, biokinetics, and bioavailability,\u201d Annual Review of Nutrition<\/em>, vol. 10, pp. 357\u2013382, 1990.<\/li>\n
  45. K. U. Ingold, V. W. Bowry, R. Stocker, and C. Walling, \u201cAutoxidation of lipids and antioxidation by \u03b1<\/em>-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein,\u201d Proceedings of the National Academy of Sciences of the United States of America<\/em>, vol. 90, no. 1, pp. 45\u201349, 1993.<\/li>\n
  46. A. Azzi, R. Ricciarelli, and J.-M. Zingg, \u201cNon-antioxidant molecular functions of \u03b1<\/em>-tocopherol (vitamin E),\u201d FEBS Letters<\/em>, vol. 519, no. 1\u20133, pp. 8\u201310, 2002.<\/li>\n
  47. J. K. Lodge, \u201cMass spectrometry approaches for vitamin E research,\u201d Biochemical Society Transactions<\/em>, vol. 36, no. 5, pp. 1066\u20131070, 2008.<\/li>\n
  48. H. Kamin, \u201cStatus of the 10th edition of the recommended dietary allowances\u2014prospects for the future,\u201d The American Journal of Clinical Nutrition<\/em>, vol. 41, no. 1, pp. 165\u2013170, 1985.<\/li>\n
  49. M. G. Traber, D. Rader, R. V. Acuff, R. Ramakrishnan, H. B. Brewer, and H. J. Kayden, \u201cVitamin E dose-response studies in humans with use of deuterated RRR-\u03b1<\/em>-tocopherol,\u201d The American Journal of Clinical Nutrition<\/em>, vol. 68, no. 4, pp. 847\u2013853, 1998.<\/li>\n
  50. M. K. Horwitt, \u201cVitamin E: a reexamination,\u201d The American Journal of Clinical Nutrition<\/em>, vol. 29, no. 5, pp. 569\u2013578, 1976.<\/li>\n
  51. E. Herrera and C. Barbas, \u201cVitamin E: action, metabolism and perspectives,\u201d Journal of Physiology and Biochemistry<\/em>, vol. 57, no. 2, pp. 43\u201356, 2001.<\/li>\n
  52. S. E. Benner, R. J. Winn, S. M. Lippman, et al., \u201cRegression of oral leukoplakia with \u03b1<\/em>-tocopherol: a community clinical oncology program chemoprevention study,\u201d The Journal of the National Cancer Institute<\/em>, vol. 85, no. 1, pp. 44\u201347, 1993.<\/li>\n
  53. K. A. Naidu, \u201cVitamin C in human health and disease is still a mystery? An overview,\u201d Nutrition Journal<\/em>, vol. 2, pp. 1\u201310, 2003.<\/li>\n
  54. A. B. Kallner, D. Hartmann, and D. H. Hornig, \u201cOn the requirements of ascorbic acid in man: steady-state turnover and body pool in smokers,\u201d The American Journal of Clinical Nutrition<\/em>, vol. 34, no. 7, pp. 1347\u20131355, 1981.<\/li>\n
  55. B. Frei, L. England, and B. N. Ames, \u201cAscorbate is an outstanding antioxidant in human blood plasma,\u201d Proceedings of the National Academy of Sciences of the United States of America<\/em>, vol. 86, no. 16, pp. 6377\u20136381, 1989.<\/li>\n
  56. M. Levine, C. Conry-Cantilena, Y. Wang, et al., \u201cVitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance,\u201d Proceedings of the National Academy of Sciences of the United States of America<\/em>, vol. 93, no. 8, pp. 3704\u20133709, 1996.<\/li>\n
  57. Hayasaki K, Kitamura T, Kaneko T ef al<\/em>. <\/em><\/strong>Application of BLMiontophoresis for the tumour therapy of the head and neck area. J Jpn Soc Cancer Therapy <\/em>1977; 12:522-527.<\/li>\n
  58. Hisano Y, <\/strong>Satoh T, Suzuki M, Kanai Y. An effective case of local injection therapy of <\/em><\/strong>oral leukoplakia with bleomycin. Shigaku <\/em>1978; 66:<\/li>\n
  59. Hammersley N, Ferguson MM, Rennie JS. Topical bleomycin in the treatment of oral leukoplakia: A pilot study. Brit <\/em>J Oral Maxillofac Surg <\/em>1985; 23:251-258.<\/li>\n
  60. Pharmacokinetic and chemoprevention studies on tea in humans, H.-H. Sherry Chowa,\u2217, Iman A. Hakim Pharmacological Research 64 (2011) 105\u2013 112<\/li>\n
  61. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha\u2011Tocopherol Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029\u201135.<\/li>\n
  62. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997; 3:515\u201322. [PubMed: 9815714]<\/li>\n
  63. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13:3\u201317. [PubMed: 1313356]<\/li>\n
  64. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 1988; 48:6753\u20137. [PubMed: 2460228]<\/li>\n
  65. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994; 54:3153\u20139. [PubMed: 8205534]<\/li>\n
  66. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996; 78:1284\u201392. [PubMed: 8826952]<\/li>\n
  67. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359:1143\u201354. [PubMed: 18784104]<\/li>\n
  68. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006; 55:115\u201322. [PubMed: 16118353]<\/li>\n
  69. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003; 4:431\u20136. [PubMed: 14706335]<\/li>\n
  70. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005; 23:254\u201366. [PubMed: 15637389]<\/li>\n
  71. Cohen EG, Almahmeed T, Du B, Golijanin D, Boyle JO, Soslow RA, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res. 2003; 9:3425\u201330. [PubMed: 12960132]<\/li>\n
  72. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999; 59:991\u20134. [PubMed: 10070952]<\/li>\n
  73. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004; 10:5930\u20139. [PubMed: 15355926]<\/li>\n
  74. 79. GM Gaeta, F Gombos, F Femiano, C Battista, P Minghetti, L Montanari, RA Satriano, G Aruenziano, Journal of the European Academy of Dermatology and Venereology, 2000, 14, 473-478,<\/li>\n
  75. A. Si\u00b4eron, G. Namyslowski, M. Misiolek, M. Adamek, and A. Kawczyk-Krupka, \u201cPhotodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers,\u201d European Archives of Oto-Rhino-Laryngology<\/em>, vol. 258, no. 7, pp. 349\u2013352, 2001.<\/li>\n
  76. A. C. K\u00a8ubler, \u201cPhotodynamic therapy,\u201d Medical Laser Application<\/em>, vol. 20, no. 1, pp. 37\u201345, 2005.<\/li>\n
  77. K. Konopka and T. Goslinski, \u201cPhotodynamic therapy in dentistry,\u201d Journal of Dental Research<\/em>, vol. 86, no. 8, pp. 694\u2013707, 2007.<\/li>\n
  78. C. J. Kelty, N. J. Brown, M. W. R. Reed, and R. Ackroyd, \u201cThe use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis,\u201d Photochemical and Photobiological Sciences<\/em>, vol. 1, no. 3, pp. 158\u2013168, 2002.<\/li>\n
  79. H.-M. Chen, C.-H. Yu, P.-C. Tu, C.-Y. Yeh, T. Tsai, and C.-P. Chiang, \u201cSuccessful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy,\u201d Lasers in Surgery and Medicine<\/em>, vol. 37, no. 2, pp. 114\u2013122, 2005.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction OL is a predominantly white lesion of the oral […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3732","post","type-post","status-publish","format-standard","hentry","category-vol8octoberspledition"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/3732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=3732"}],"version-history":[{"count":3,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/3732\/revisions"}],"predecessor-version":[{"id":4801,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/3732\/revisions\/4801"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=3732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=3732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=3732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}